Mammalian Type I Gonadotropin-Releasing Hormone Receptors Undergo Slow, Constitutive, Agonist-Independent Internalization

Medical Research Council Human Reproductive Sciences Unit, The Queen's Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, United Kingdom.
Endocrinology (Impact Factor: 4.5). 04/2008; 149(3):1415-22. DOI: 10.1210/en.2007-1159
Source: PubMed


Regulatory elements present in the cytoplasmic carboxyl-terminal tails of G protein-coupled receptors contribute to agonist-dependent receptor desensitization, internalization, and association with accessory proteins such as beta-arrestin. The mammalian type I GnRH receptors are unique among the rhodopsin-like G protein-coupled receptors because they lack a cytoplasmic carboxyl-terminal tail. In addition, they do not recruit beta-arrestin, nor do they undergo rapid desensitization. By measuring the internalization of labeled GnRH agonists, previous studies have reported that mammalian type I GnRH receptors undergo slow agonist-dependent internalization. In the present study, we have measured the internalization of epitope-tagged GnRH receptors, both in the absence and presence of GnRH stimulation. We demonstrate that mammalian type I GnRH receptors exhibit a low level of constitutive agonist-independent internalization. Stimulation with GnRH agonist did not significantly enhance the level of receptor internalization above the constitutive level. In contrast, the catfish GnRH and rat TRH receptors, which have cytoplasmic carboxyl-terminal tails, displayed similar levels of constitutive agonist-independent internalization but underwent robust agonist-dependent internalization, as did chimeras of the mammalian type I GnRH receptor with the cytoplasmic carboxyl-terminal tails of the catfish GnRH receptor or the rat TRH receptor. When the carboxyl-terminal Tyr325 and Leu328 residues of the mammalian type I GnRH receptor were replaced with alanines, these two mutant receptors underwent significantly impaired internalization, suggesting a function for the Tyr-X-X-Leu sequence in mediating the constitutive agonist-independent internalization of mammalian type I GnRH receptors. These findings provide further support for the underlying notion that the absence of the cytoplasmic carboxyl-terminal tail of the mammalian type I GnRH receptors has been selected for during evolution to prevent rapid receptor desensitization and internalization to allow protracted GnRH signaling in mammals.

Download full-text


Available from: Stuart Maudsley,
  • Source
    • "Some species have been shown to be particularly resistant to rapid desensitization by GnRH agonists at the pituitary level because they have evolved cell surface GnRH receptors that are slow to internalize (lacking a phosphorylated tail on the receptor) making desensitization and eventual downregulation take longer or never occur [Pawson et al., 2008]. Perhaps female sea otters have this special adaptation within GnRH cell surface receptors in both the pituitary and perhaps the ovaries as well to prevent rapid desensitized to GnRH stimulation as an adaptation to protracted high reproductive hormone levels needed for effective ovulation and the maintenance of a long lived corpus luteum observed in this species [Aspden et al., 1996; Larson et al., 2003; Pawson et al., 2008]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The sea otter (Enhydra lutris) is a popular exhibit animal in many zoos and aquariums worldwide. Captive sea otters from these populations are owned by the United States Fish and Wildlife Service (USFWS). The USFWS has requested that these sea otters be prevented from breeding in order to save captive space for wild rescued animals. Sea otters are often housed in mixed sex groups, therefore a chemical contraceptive method or surgical removal of gonads must be used to prevent potential pregnancy. The contraceptive, Suprelorin® or deslorelin, has been used in many different species to effectively suppress reproduction but duration of effect may vary not only between species but also individuals. Here, we report the effects of one to several consecutive deslorelin implants on gonadal reproductive hormones found in fecal samples from six captive sea otters (two males and four females) compared to two control otters (one male and one female) housed at three zoological institutions. We documented the longitudinal hormone signatures of many stages of the contraceptive cycle including pretreatment (PT), stimulatory phase (S), effective contraception (EC), and hormone reversal (HR) that was characterized by a return to normal hormone levels. Deslorelin was found to be an effective contraceptive in sea otters and was found to be reversible documented by a live birth following treatment, however the duration of suppression in females was much longer than expected with a 6-month and a 1-year implant lasting between 3 and 4 years in females. Zoo Biol. 32:307–315, 2013. © 2012 Wiley Periodicals, Inc.
    Zoo Biology 05/2013; 32(3). DOI:10.1002/zoo.21032 · 0.83 Impact Factor
  • Source
    • "Whereas these studies were rather measuring ligand internalization, investigations conducted by Millar's group, using an epitope-tagged receptor allowed to trace the receptor itself. These studies established that GnRH-R exhibits a low level of constitutive internalization and does not undergo rapid agonistdependent internalization as compared to non-mammalian GnRH or the TSH-releasing hormone receptors (Pawson et al., 2008). The refractory state of gonadotrope cells under a sustained GnRH challenge is thus believed to occur through desensitization mechanism affecting downstream signaling entities such as Gαq/11, PKC isoforms , or IP3 receptors (Willars et al., 2001; Liu et al., 2003) rather than the receptor itself. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The gonadotropin-releasing hormone (GnRH) pulsatile pattern is critical for appropriate regulation of gonadotrope activity but only little is known about the signaling mechanisms by which gonadotrope cells decode such pulsatile pattern. Here, we review recent lines of evidence showing that the GnRH receptor (GnRH-R) activates the cyclic AMP (cAMP) pathway in gonadotrope cells, thus ending a long-lasting controversy. Interestingly, coupling of GnRH-R to the cAMP pathway as well as induction of nitric oxide synthase 1 (NOS1) or follistatin through this signaling pathway take place preferentially under high GnRH pulsatility. The preovulatory surge of GnRH in vivo is indeed associated with an important increase of pituitary cAMP and NOS1 expression levels, both being markedly inhibited by treatment with a GnRH antagonist. Altogether, this suggests that due to its atypical structure and desensitization properties, the GnRH-R may continue to signal through the cAMP pathway under conditions inducing desensitization for most other receptors. Such a mechanism may contribute to decode high GnRH pulsatile pattern and enable gonadotrope cell plasticity during the estrus cycle.
    Frontiers in Endocrinology 08/2012; 3:107. DOI:10.3389/fendo.2012.00107
  • Source
    • "desensitization of the GnRH receptor and, hence, medical castration (Maudsley et al., 2004; Pawson et al., 2008). Moreover , according to their " dual pharmacology, " GnRH analogs are also characterized by direct anticancer potential via their interference with growth and survival factors, such as insulin-like growth factor-I, epidermal growth factor, and keratinocyte growth factor (Culig et al., 1994; Montagnani Marelli et al., 2007). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Gonadotropin-releasing hormone (GnRH) receptor agonists have wide clinical applications including the treatment of prostate cancer and endocrine disorders. However, such agonists are characterized by poor pharmacokinetic properties, often requiring repeated administration or special formulations. Therefore, the development of novel peptide analogs with enhanced in vivo stability could potentially provide therapeutic alternatives. The pharmacological evaluation of a bioactive peptide [Des-Gly¹⁰,Tyr⁵(OMe),D-Leu⁶,Aze-NHEt⁹]GnRH, analog 1, is presented herein and compared with leuprolide. Peptide stability was evaluated using mouse kidney membrane preparations, followed by a liquid chromatography-tandem mass spectrometry-based approach that afforded identification and quantification of its major metabolites. The analog was significantly more stable in vitro in comparison with leuprolide. In vitro and in vivo stability results correlated well, encouraging us to develop a clinically relevant pharmacokinetic mouse model, which facilitated efficacy measurements using testosterone as a biomarker. Analog 1, an agonist of the GnRH receptor with a binding affinity in the nanomolar range, caused testosterone release in mice that was acutely dose-dependent, an effect blocked by the GnRH receptor antagonist cetrorelix. Repeated dosing studies in mice demonstrated that analog 1 was well tolerated and had potency similar to that of leuprolide, based on plasma and testis testosterone reduction and histopathological findings. Analog 1 also shared with leuprolide similar significant antiproliferative activity on androgen-dependent prostate cancer (LNCaP) cells. On the basis of pharmacokinetic advantages, we expect that analog 1 or analogs based on this new design will be therapeutically advantageous for the treatment of cancer and endocrine disorders.
    Journal of Pharmacology and Experimental Therapeutics 03/2011; 336(3):613-23. DOI:10.1124/jpet.110.174375 · 3.97 Impact Factor
Show more